Sep 6 2007
Polymer Technology Group, a preeminent biomaterials company, announced today that it has tripled its R&D and manufacturing capacity by expanding existing operations in the Temescal Business Park of Berkeley, Calif., to 53,000 square feet. PTG is now one of the largest biomaterials companies in the medical device industry.
“PTG has truly pioneered the analysis of biomaterial surfaces and interfaces,” said Dr. Gabor Somorjai, a distinguished professor of chemistry at the University of California/Berkeley, who also is Director of the Surface Science and Catalysis Program at Lawrence Berkeley National Laboratory, where 11 Nobel Laureates are employed. “There is no doubt, absolutely, that Bob Ward and PTG have driven the development of novel biomedical products that are significantly benefiting mankind. What PTG has done is to increase its scientific understanding of why things work, why things don’t work, and based on their knowledge have developed a whole new generation of biomaterials. They are an extremely important company in the biomaterials sector of the medical device industry.”
Robert S. (Bob) Ward, Founder, President and CEO, added, “We are pleased that the growth of our biomaterials and medical device component business has resulted in the need for significant expansion of our operations. Our new R&D facility includes a state-of-the-art laboratory and pilot plant for new polymer materials development. This expansion also increases the efficiency of our production scale polymer synthesis and medical device components manufacturing.”